David Tanen is a co-founder of Two River, LLC, a life science consulting and investment firm, where he has served as a partner since its inception in September 2004. He has also served as an advisor to Vida Ventures, a life science venture capital firm since November 2018. Mr. Tanen was a co-founder of Kite Pharma, Inc., where he served as Corporate Secretary and General Counsel from June 2009 until its acquisition by Gilead Sciences in 2017. He is a co-founder of Allogene Therapeutics, Inc. and has served as its Corporate Secretary since its inception in December 2017. Mr. Tanen also served as an officer and director of Neogene Therapeutics, Inc. until its acquisition by AstraZeneca in January 2023.
Mr. Tanen received his B.A. from The George Washington University and his J.D. from Fordham University School of Law, where he has served on the Dean’s Planning Council since 2009. Mr. Tanen has also served as a member of the Board of Trustees of Fordham University since June 2023.